Welcome to Alimera Sciences Europe

Alimera Sciences Inc. Founded in June 2003, and proudly established as Alimera Sciences Limited in Europe since 2013, is a pharmaceutical company that specialises in the commercialisation and development of prescription ophthalmic pharmaceuticals. Alimera Sciences is presently focused on diseases affecting the back of the eye, or retina, because these diseases may be insufficiently treated with current therapies and affect millions of people in our aging populations.

Alimera's focus is to:
  • Continue development of our current product portfolio in pursuit of other potential ophthalmic indications.

  • Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.

  • Operate as an ethically driven company, recognizing our responsibility to others and the importance of having a positive impact on those with whom we interact.

Date of preparation: March 2019

Leadership team

The Alimera Sciences management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and is dedicated and focused in making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialisation of ophthalmic products.


Richard S. Eiswirth, Jr.

President and Chief Financial Officer

Richard S. Eiswirth, Jr. was promoted to President and Chief Executive Officer effective January 2, 2019. Mr. Eiswirth previously served as President and Chief Financial Officer of our Company since January 2016; our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.


Philip Ashman, Ph.D.

Chief Operating Officer, Senior Vice President, Commercial Operations Europe

Philip Ashman, Ph.D. has served as the Chief Operating Officer, Senior Vice President, Commercial Operations Europe since January 2, 2019. Prior to this position he was Senior Vice President and managing Director Europe since January 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, most recently responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including Ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.

Dave Holland

David Holland

Chief Marketing Officer, Senior Vice President Corporate Communications

David Holland is one of our co-founders and has served as our Chief Marketing Officer, Senior Vice President Corporate Communications since January 2, 2019. Prior to this, he was Senior Vice President U.S. Sales and Marketing from August 2010 through December 2018. Mr. Holland was the Vice President of Marketing since the founding of our Company in 2003 through August 2010. Prior to founding our Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.

Phil Jones

Chief Financial Officer

Mr. Jones has been our Chief Financial officer since January 2, 2019. From August 2016, he served as the Company’s Vice President of Finance and Assistant Corporate Secretary and joined Alimera in June of 2015 as Corporate Controller. Prior to Alimera, Mr. Jones held various senior financial leadership roles in Theragenics Corporation, a medical product manufacturing company, Superior Essex, a communications cable company, and Arjo Wiggins Medical, the medical materials division of Arjo Wiggins Appleton plc. Mr. Jones began his financial career in 1986 as an auditor for a large CPA firm in Atlanta, Georgia. Mr. Jones is a Certified Public Accountant in the state of Georgia and is a graduate of Auburn University with a B.S.B.A. degree with a concentration in accounting.

Kenneth Green

Kenneth Green, Ph.D. 

Chief Scientific Officer

Kenneth Green, Ph.D. joined us in 2004 as Vice President of Scientific Affairs and has served as the Senior Vice President and Chief Scientific Officer of our Company since January 2007. Prior to joining us, Dr. Green served as the Vice President Global Head of Clinical Sciences at Novartis Ophthalmics. He has managed ophthalmic clinical development organizations at Storz Ophthalmics, Bausch & Lomb and CIBA Vision. He started his career in the pharmaceutical industry in 1984, as a basic research scientist in drug discovery at Lederle Laboratories and has since held positions in many areas of drug development.  Dr. Green holds a Bachelor of Arts in Chemistry from Southern Illinois University and a Ph.D. in Organic Chemistry from Ohio State University.

Executive Leadership

Adrian Simpson

Adrian Simpson

Country Manager, UK & Ireland

Adrian Simpson is Country Manager for the UK & Ireland of Alimera Sciences since January 2018. He has nearly 30 years industry experience with much of the last 20 years holding Regional, Divisional, National and Country Manager roles, along with numerous cross function and country responsibilities, in the past 10 years he has had extensive experience focusing on the commercialisation of niche and speciality products to the UK and Irish markets within small to medium specialist pharma. Alongside this wealth of experience and knowledge in these sectors, his real passion and focus sits within sales force effectiveness and the evolution of CRM development to drive success.


Carlos Augusto

Managing Director, Portugal & Spain

Carlos Augusto joined Alimera Sciences as Country Manager Portugal in July 2014. 2015 has seen his responsibilities extend to management of Alimera Sciences activities in Spain. He has 16 years of experience in the Pharmaceutical Industry in several Sales and Marketing Managerial roles across different companies. He started his experience in Ophthalmology in 2008 at Merck Sharp & Dohme Portugal, where he held roles in Marketing and Sales. Carlos holds a degree in Marketing Management.


Date of preparation: March 2019

View our leadership team

This link will take you away from

Date of preparation: April 2019

For more information Contact us